Biologic Modifiers and Chemoprevention of Cancer of the Oral Cavity
Author:
- William J. RichtsmeierWRWilliam J. Richtsmeier
- 7 January 1993
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 328 (1) , 58-59
Abstract
An oncologist beginning the study of squamous-cell carcinoma of the upper aerodigestive tract is often overwhelmed by the differences in presentation, staging, biologic behavior, and treatment depending on the precise site in the head and neck. In considering the importance of the report by Lippman et al. in this issue of the Journal,1 readers who are not oncologists need to place the cancers studied in perspective. Are squamous-cell carcinomas of the head and neck different from other squamous-cell carcinomas, and is a tumor in the oral cavity different from one elsewhere in the head and neck? It is true that . . .Keywords
This publication has 3 references indexed in Scilit:
- Comparison of Low-Dose Isotretinoin with Beta Carotene to Prevent Oral CarcinogenesisNew England Journal of Medicine, 1993
- Phase I-II Study of Advanced Head and Neck Squamous Cell Carcinoma Patients Treated With Recombinant Human Interferon GammaJAMA Otolaryngology–Head & Neck Surgery, 1990
- Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 1990